Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Neusignal Therapeutics has raised $32.8M in total funding. The most recent round was Series B. The last funding was announced in June 2026.
Neusignal Therapeutics's investors include Red Capital, Mitsubishi UFJ Capital, Nissay Capital, Mizuho Capital, SMBC Venture Capital.
Neusignal Therapeutics is headquartered in Tokyo, Japan.
Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Neusignal Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neusignal Therapeutics — Funding & Investors." VCBacked, June 30, 2026, https://www.vcbacked.co/company/neusignal-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). Neusignal Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/neusignal-therapeutics
{{cite web |title=Neusignal Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/neusignal-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated